8-K: Zymeworks Reports Full Year 2023 Financial Results and Provides Business Update

Zymeworks announced its full year 2023 financial results, highlighting a strong cash position and progress in its clinical development programs, including the initiation of a rolling BLA submission for zanidatamab.

Summary

• Zymeworks reported a net loss of $118.7 million for 2023, compared to a net income of $124.3 million in 2022, primarily due to a decrease in upfront fees from the Jazz partnership.
• Revenue for 2023 was $76.0 million, a significant decrease from $412.5 million in 2022, which included a large upfront payment from Jazz.
• The company's cash resources stood at $456.3 million as of December 31, 2023, which, combined with anticipated regulatory milestone payments, is expected to fund operations into the second half of 2027.
• Zymeworks is advancing its pipeline, with a rolling BLA submission for zanidatamab initiated in the US and a planned submission in China in the second half of 2024.
• The company is also progressing its early-stage programs, with two IND submissions planned for 2024 and additional submissions planned over the next two years.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strong cash position and progress in clinical development, but tempered by the significant decrease in revenue and the net loss for the year.

Positives

• The company has a strong cash position of $456.3 million, providing a cash runway into the second half of 2027.
• The initiation of the rolling BLA submission for zanidatamab in the US is a significant step towards potential regulatory approval.
• The advancement of the early-stage pipeline with two planned IND submissions in 2024 demonstrates continued progress in research and development.
• The company has reduced its operating cash burn and operating losses during 2023 compared to 2022.
• The increase in enrollment for the HERIZON-GEA-01 trial is aimed at improving the statistical power for the overall survival endpoint.

Negatives

• The company experienced a significant decrease in revenue from $412.5 million in 2022 to $76.0 million in 2023, primarily due to the absence of a large upfront payment from Jazz.
• Zymeworks reported a net loss of $118.7 million in 2023, compared to a net income of $124.3 million in 2022.
• The planned Phase 2 study for zanidatamab zovodotin has been deprioritized, pending more clarity from the evolving clinical landscape.

Risks

• The company's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable.
• Zymeworks may not achieve milestones or receive additional payments under its collaborations.
• Regulatory agencies may impose additional requirements or delay the initiation of clinical trials.
• Clinical trials may not demonstrate the safety and efficacy of the company's product candidates.
• The company's assumptions and estimates regarding its financial condition, future financial performance, and estimated cash runway may be incorrect.
• Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Zymeworks anticipates a transformative year with potential regulatory approvals and the execution of its development strategy for its early-stage pipeline, with a cash runway into the second half of 2027.

Management Comments

• We begin 2024 in a very strong position, with the initiation of the rolling BLA submission for zanidatamab in second-line BTC in the United States, and a projected cash runway to support the development of our expanded portfolio of clinical and preclinical product candidates into the second half of 2027, said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
• We remain on track with our goal of completing two IND submissions this year, with multiple data catalysts highlighting the innovation within our pipeline, said Kenneth Galbraith.
• We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022, said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
• Our strategy of re-focusing the business and building a diverse clinical-stage product pipeline of ADCs and multispecific antibody therapeutics continues to provide a strong foundation, helping to achieve our long-term goal of identifying additional product candidates and seeking valuable partnership options, while also maintaining our cash runway, said Chris Astle, Ph.D.

Industry Context

This announcement reflects the ongoing development and regulatory progress in the biotechnology sector, particularly in the area of cancer therapeutics. The company's focus on bispecific antibodies and antibody-drug conjugates aligns with current trends in the industry.

Comparison to Industry Standards

• Zymeworks' cash runway into the second half of 2027 is a positive indicator compared to many other clinical-stage biotech companies that often face near-term funding challenges.
• The initiation of a rolling BLA submission for zanidatamab is a significant milestone, comparable to other companies advancing novel cancer therapies through regulatory pathways.
• The company's focus on both antibody-drug conjugates (ADCs) and multispecific antibodies is in line with the industry's trend towards developing more targeted and effective cancer treatments, similar to companies like Seagen and Regeneron.
• The decrease in revenue from 2022 to 2023 is a common occurrence for biotech companies that rely on milestone payments and upfront fees, and is similar to the revenue fluctuations seen in other companies with partnership agreements.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the strong cash position and pipeline progress.
• Employees may be affected by the restructuring and changes in headcount, but the company's focus on growth and development may provide opportunities.
• Customers and partners may benefit from the advancement of the company's product candidates and potential regulatory approvals.
• Creditors may be reassured by the company's strong cash position and projected cash runway.

Next Steps

• Complete the rolling BLA submission for zanidatamab in the US in the first half of 2024.
• Submit a BLA for zanidatamab in China in the second half of 2024.
• Achieve a readout for the HERIZON-GEA-01 pivotal Phase 3 trial in late 2024.
• Submit two IND or foreign equivalent submissions for ZW191 and ZW171 in 2024.
• Nominate the fifth IND candidate during 2024, with a planned IND filing in 1H 2026.

Key Dates

Keywords

Zymeworks, zanidatamab, biologics license application, BLA, biliary tract cancers, BTC, HER2, antibody-drug conjugates, multispecific antibodies, clinical trials, IND, regulatory approval, cash runway, Jazz Pharmaceuticals, BeiGene